| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.82% | 98.25% | 73.71% | 95.58% | 95.53% | — | — | — | — |
| Operating Margin | -104.25% | -267.22% | -6528.75% | -659.65% | -827.12% | -5751.99% | -656.41% | — | — |
| EBITDA Margin | -103.17% | -264.49% | -6458.95% | -650.93% | -818.73% | -5734.34% | -654.29% | — | — |
| Net Margin | -145.98% | -244.86% | -7021.94% | -624.17% | -841.20% | -6127.87% | -711.50% | — | — |
| Current Ratio | 2.77 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | — |
| Quick Ratio | 2.68 | 4.67 | 3.32 | 4.52 | 6.58 | 6.72 | 9.42 | 13.67 | — |
| Debt / Equity | -0.97 | -0.30 | -0.33 | -0.35 | -0.50 | 0.88 | 0.19 | 0.14 | — |
| ROE | 35.31% | 37.27% | 48.64% | 38.98% | 67.64% | -475.73% | -60.92% | -44.92% | — |
| ROA | -78.30% | -59.10% | -119.56% | -77.79% | -57.90% | -71.84% | -45.69% | -36.45% | — |
| Asset Turnover | 0.54 | 0.24 | 0.02 | 0.12 | 0.07 | 0.01 | 0.06 | — | — |
| Book Value / Share | -10.84 | -7.83 | -8.25 | -8.43 | -6.01 | 0.90 | 4.51 | — | — |
BridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for patients with genetic diseases and genetically driven cancers. The company concentrates on conditions with well-defined genetic causes, aiming to design targeted therapies that address the underlying molecular mechanisms driving these disorders. Its portfolio spans programs in areas such as rare inherited diseases, cardiology, neurology, and oncology, often targeting pathways where a clear genetic mutation or alteration has been identified. BridgeBio Pharma, Inc. partners with academic institutions, clinicians, and patient communities to identify high-impact targets and advance them through clinical development. The company also emphasizes rigorous scientific validation, reflected in a broad base of peer-reviewed research supporting its programs. Founded in the United States, BridgeBio Pharma, Inc. plays a significant role in the biopharmaceutical market by focusing on high unmet medical needs where precision medicine approaches can offer differentiated treatment options for patients with limited existing therapies.